Juniper Pharmaceuticals Inc (JNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Juniper Pharmaceuticals Inc (JNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH63040D
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Juniper Pharmaceuticals Inc (Juniper), formerly Columbia Laboratories, Inc. is a women's health therapeutic company which focuses on developing, manufacturing, licensing and sale of pharmaceutical products in women's health. The company utilizes proprietary drug delivery technologies to treat various medical conditions to commercial partners. Its proprietary technology includes intravaginal ring (IVR) and bioadhesive gel (BDS). Juniper provides a range of drug development services and consulting services to the pharmaceutical industry. The company operates in pharmaceutical industry and also provides in-house expertise for internal pharmaceutical programs. The company operates in US, UK, Switzerland and other countries. Juniper is headquartered in Boston, Massachusetts, the US.

Juniper Pharmaceuticals Inc (JNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Juniper Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Juniper Pharma Acquires Three New Products to its Proprietary Pipeline 12

Partnerships 12

Juniper Pharma Services Enters into Agreement with Crystec Pharma 12

Molecular Profiles Enters Into Co-Development Agreement With Telormedix 13

Molecular Profiles Enters Into Agreement With Onyx Scientific 14

Licensing Agreements 15

Columbia Labs Enters into Licensing Agreement for IVR Technology 15

Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 16

Columbia Labs Enters Into Licensing Agreement With Invaron Pharma For STRIANT 17

Columbia Labs Enters Into Licensing Agreement With Actient Pharma 17

Asset Transactions 18

Lil' Drug Store Exercises Option to Acquire Rights for Legatrin PM from Columbia Labs for USD2.2 Million 18

Actient Pharma Acquires US Rights Of STRIANT From Columbia Labs 19

Acquisition 20

Columbia Labs Acquires Molecular Profiles For US$25 Million 20

Juniper Pharmaceuticals Inc-Key Competitors 22

Key Employees 23

Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

May 04, 2017: Juniper Pharmaceuticals Reports First Quarter 2017 Financial and Operating Results 25

Mar 07, 2017: Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results 27

Nov 15, 2016: Juniper Pharmaceuticals Reports Third Quarter 2016 Financial Results 29

Aug 04, 2016: Juniper Pharmaceuticals Reports Second Quarter 2016 Financial Results 31

May 04, 2016: Juniper Pharmaceuticals Reports First Quarter 2016 Financial Results 33

Mar 10, 2016: Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results 35

Corporate Communications 37

Dec 20, 2016: Juniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial Officer 37

Jul 20, 2016: Juniper Pharmaceuticals Appoints Alicia Secor President and Chief Executive Officer 38

Jun 02, 2016: Juniper Pharmaceuticals Announces Planned Retirement of CEO Frank Condella 39

Mar 24, 2016: Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors 40

Jan 20, 2016: Prominent Physicians Join Juniper Pharmaceuticals' Scientific Advisory Board 41

Product News 42

01/11/2016: Juniper Pharma Provides Update on JNP-0201 42

Product Approvals 43

Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product 43

Clinical Trials 44

Jan 11, 2016: Juniper Pharma Expands Lead Phase 2b Trial of COL-1077 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45

List of Figures

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Juniper Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Juniper Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Juniper Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Juniper Pharma Acquires Three New Products to its Proprietary Pipeline 12

Juniper Pharma Services Enters into Agreement with Crystec Pharma 12

Molecular Profiles Enters Into Co-Development Agreement With Telormedix 13

Molecular Profiles Enters Into Agreement With Onyx Scientific 14

Columbia Labs Enters into Licensing Agreement for IVR Technology 15

Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 16

Columbia Labs Enters Into Licensing Agreement With Invaron Pharma For STRIANT 17

Columbia Labs Enters Into Licensing Agreement With Actient Pharma 17

Lil' Drug Store Exercises Option to Acquire Rights for Legatrin PM from Columbia Labs for USD2.2 Million 18

Actient Pharma Acquires US Rights Of STRIANT From Columbia Labs 19

Columbia Labs Acquires Molecular Profiles For US$25 Million 20

Juniper Pharmaceuticals Inc, Key Competitors 22

Juniper Pharmaceuticals Inc, Key Employees 23

Juniper Pharmaceuticals Inc, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Juniper Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16090
Site License
USD 500 INR 32180
Corporate User License
USD 750 INR 48270

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com